|
|
|
|
| LEADER |
01844nam a2200301 u 4500 |
| 001 |
EB002001312 |
| 003 |
EBX01000000000000001164213 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.)
|
| 246 |
3 |
1 |
|a Pharmacoeconomic review report for Adlyxine
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, December 2017
|
| 300 |
|
|
|a 1 PDF file (28 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Diabetes Mellitus, Type 2 / drug therapy
|
| 653 |
|
|
|a Hypoglycemic Agents / economics
|
| 653 |
|
|
|a Glucagon-Like Peptide-1 Receptor / agonists
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK534150
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Lixisenatide (Adlyxine) is a glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes mellitus in patients uncontrolled on basal insulin with or without oral glucose-lowering agents. The starting dose is 10 mcg once daily for 14 days, then increased to 20 mcg once daily. It is supplied as a solution in a pre-filled injector pen for subcutaneous administration in strengths of 0.05 mg/mL and 0.1 mg/mL, delivering 14 doses of 10 mcg per dose or 20 mcg per dose. The submitted price of lixisenatide is $56.98 per injector pen (regardless of strength) or $1,486 annually
|